- Home
- EOI vs CMPX Comparison
EOI vs CMPX Comparison
Compare EOI & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
EOI
Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Current Price
Company Overview
Basic Information| Metric | EOI | CMPX |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 805.7M | 752.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EOI | CMPX |
|---|---|---|
| Price | $20.53 | $5.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $13.44 |
| AVG Volume (30 Days) | 83.6K | ★ 1.8M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 7.19% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.36 | $1.33 |
| 52 Week High | $18.88 | $5.86 |
Technical Indicators
Market Signals| Indicator | EOI | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 65.28 | 52.83 |
| Support Level | $20.14 | $4.83 |
| Resistance Level | $20.62 | $5.27 |
| Average True Range (ATR) | 0.23 | 0.25 |
| MACD | 0.12 | -0.04 |
| Stochastic Oscillator | 93.48 | 50.82 |
Price Performance
Historical ComparisonAbout EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation. The company's sector allocation includes: Information Technology, Communication Services, Financials, Consumer Discretionary, Healthcare, Industries, Consumer Staples, Energy, Real Estate, and Materials.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.